The Cancer Prevention & Research Institute of Texas is adding rare cancers and childhood cancers to its list of funding priorities, according to a draft program report.
The FDA Oncologic Drugs Advisory Committee recommended against approval of the Novartis agent Farydak (panobinostat), a pan-deacetylase inhibitor, for the indication of previously treated multiple myeloma when used in combination with bortezomib and dexamethasone.
FDA approved Avastin in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
This week the Centers for Medicare & Medicaid Services issued a proposed rule stating that the scientific evidence was sufficient to support reimbursement for counseling on the risks and benefits of lung cancer screening as well as lung cancer screening with low dose computed tomography in high risk individuals and once per year. CMS will pay for such services when provided to beneficiaries at high risk for lung cancer and when provided by physicians and centers with specific qualifications.
CT screening of the lungs of current and former heavy smokers is about to become a Medicare benefit.
NCI is hosting a Small Business Innovation Research Investor Forum Nov. 13 at Agilent Technologies in Santa Clara, Calif., where 28 SBIR-funded companies will present cancer therapeutics, diagnostics, and devices.
FDA approved Cyramza (ramucirumab) in combination with paclitaxel as a treatment for advanced or metastatic stomach or gastroesophageal junction adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
CITY OF HOPE launched a stem cell therapy clinic. The Alpha Clinic for Cell Therapy and Innovation is funded by an $8 million, five-year grant from the California Institute for Regenerative Medicine.
STEVEN FINKELSTEIN was appointed national chief science officer of 21st Century Oncology.
DAVID NATHAN is the first recipient of the Boston Children's Hospital Lifetime Impact Award at the hospital's second annual Global Pediatric Innovation Summit.
